ProfileGDS5678 / 1453319_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 57% 65% 66% 62% 65% 63% 63% 63% 63% 63% 65% 63% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8323463
GSM967853U87-EV human glioblastoma xenograft - Control 23.4707457
GSM967854U87-EV human glioblastoma xenograft - Control 33.9028765
GSM967855U87-EV human glioblastoma xenograft - Control 44.0364966
GSM967856U87-EV human glioblastoma xenograft - Control 53.6978162
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9259865
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8221963
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.758763
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7526163
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.770763
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7861663
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9331965
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7913363
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7802163